RhoVac is a pharmaceutical company. Today, the focus is on the development of vaccines for the treatment of metastatic cancer. Immunotherapy treatment is a significant part of the operations where the body's immune system is used to fight and eliminate cancer cell. The company's drug candidate is used in combination with surgery or radiation therapy. The company was established in 2007 and is based in Lund.

Quotes for RhoVac AB

Right Now

+/-
-0.08
%
-0,50%
Latest
15.9
High
16.02
Low
15.74
Volume
5 665
Turnover (SEK)
90 048
Value (MSEK)
302,8

Board

CEO

  • Anders Månsson

Chairman Of The Board

  • Mikael Ørum

Board

  • Anders Ljungqvist
  • Cristina Glad
  • Gunnar Gårdemyr
  • Lars Hedbys

Videos

Largest Owners

Name Capital % Votes % Date
RQ Solutions ApS 14,07 14,07 2019-06-30
Ventac Holding (Cyprus) Ltd 12,49 12,49 2019-06-30
Nordic Cross Asset Management 6,86 6,86 2019-09-30
Avanza Pension 6,22 6,22 2019-06-30
Nordnet Pensionsförsäkring 3,59 3,59 2019-06-30
Nils Berntsson 2,13 2,13 2019-06-30
John Bäck 1,55 1,55 2019-06-30
Ola Forsman 1,41 1,41 2019-06-30
Anders Bremer 1,31 1,31 2019-06-30
Björn Tommy Atterling 1,05 1,05 2019-06-30
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

Key Numbers

*Compiled data from Millistream

Upcoming reports

  • 2019-11-15 Delårsrapport 2019-Q3

  • 2020-02-11 Bokslutskommuniké 2019